Table 1.
Basic characteristics of the selected studies.
| Author(s), publication time | Sample size (cases) | Male/Female | Average age (years) | Disease type | Intervention measures | Success (cases) | Failure (cases) | Pain relief (cases) | No pain (cases) | Adverse events | Outcome indicators |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LeBlanc et al., 201317 | 10 | 5/5 | 66±14 | Pancreatic cancer-related pain | 10 mL alcohol during EUS-CPN | ‒ | ‒ | 8 | ‒ | 3 | |
| Gunaratnam et al., 200118 | 58 | 32/26 | 67.1±9.3 | Pancreatic cancer | EUS-CPN | ‒ | ‒ | 45 | ‒ | Procedure-related transient abdominal pain (5 patients) | 3 |
| LeBlanc et al., 201119 | 50 | 24/26 | 63 | Pancreatic cancer related pain | alcohol given as 1 vs. 2 injections during EUS-CPN | ‒ | ‒ | 37 | 4 | There were no long-term complications | 3, 4 |
| Wiechowska-Kozłowska et al., 201220 | 29 | ‒ | ‒ | Advanced and unresectable pancreatic cancer | EUS-CPN | ‒ | ‒ | 25 | 4 | Hypotonia (1 patient), severe pain immediately post-procedure (2 patients), short episodes of diarrhea (3 patients) | 3, 4, 5 |
| Hao et al., 201421 | 41 | 24/17 | Unresectable pancreatic cancer | EUS-CPN | ‒ | ‒ | 23 | 4 | Transient hypotension (2 patients) | 3, 4, 5 | |
| Sanders et al., 201022 | 51 | 29/22 | 73 | Either locally advanced or recurrent pancreatic cancer | EUS-SBRT | 46 | 4 | ‒ | ‒ | Mild pancreatitis (1 patient), simultaneous placement of fiducials and celiac plexus neurolysis for intractable abdominal pain (1 patient) | 1, 2, 5 |
| Sun et al., 201223 | 8 | 3/5 | 69 | Advanced pancreatic cancer | (EUS-ICR) | 4 | ‒ | ‒ | ‒ | ‒ | 1 |
| Figueiredo et al., 202124 | 37 | 20/17 | 60 | Borderline resectable/locally advanced pancreatic ductal adenocarcinoma | EUS-SBRT | 34 | 3 | ‒ | ‒ | Three patients (8 %) had adverse events (fever, mild acute pancreatitis, and biliary stent migration)" | 1, 2, 5 |
| Park et al., 201025 | 57 | 29/28 | 67 ± 12 | Locally advanced unresectable pancreatic adenocarcinoma | EUS-guided insertion of gold fiducials | 50 | 3 | ‒ | ‒ | 3 patients | 1, 2, 5 |
| Sun et al., 200626 | 15 | 8/7 | 61 | Locally advanced pancreatic cancer | EUS-guided interstitial brachytherapy | 12 | ‒ | ‒ | ‒ | Pancreatitis and pseudocyst formation (3 patients); grade III hematologic toxicity (3 patients) | 1, 5 |
| Bang et al., 201927 | 12 | 5/7 | 62.8±13.7 | Pancreatic cancer | EUS-RFA | 12 | ‒ | ‒ | ‒ | 5 patients | 5 |
| Crinò et al., 201828 | 8 | 3 (5) | 67.75 | Pancreatic adenocarcinoma | EUS-RFA was performed using 18-gauge internally cooled electrode with a 5- or 10-mm exposed tip | 8 | ‒ | ‒ | ‒ | Mild post-procedural abdominal pain (3 patients) | 5 |
| Song et al., 201629 | 6 | 1/5 | 62 | Unresectable pancreatic cancer | EUS-RFA | 6 | ‒ | ‒ | ‒ | Mild abdominal pain (2 patients) | 5 |
Note: EUS, Endoscopic Ultrasound; CPN, Celiac Plexus Neurolysis; SBRT, Stereotactic Body Radiotherapy; ICR, Interstitial Chemoradiation (EUS-ICR); RFA, Radiofrequency Ablation; Outcome Indicators: 1 EUS-guided related surgery was successful; 2 EUS-guided related surgery was failure; 3 Pain relief; 4 There was no pain after EUS-guided related surgery; 5 Adverse events.